JVCKENWOOD to Sell 3D Cell Culture Multi-Well Plate through Marketing Alliance with HCS Pharma

LILLE, France - Nov. 30, 2021 - PRLog -- Through the alliance with HCS, JVCKENWOOD aims to deploy biotechnology products in drug discovery-related fields as well as developing business related to the presymptomatic state and early diagnosis support by integrating with biodevices for specimen testing and the exosome measurement system ExoCounter in the biotechnology market.

HCS's multi-well plate for 3D cell culture

In the development of new drugs, in-vitro tests are used to examine drug efficacy and toxicity in the non-clinical stage. These tests were often conducted in 2D cell culture systems, where conditions are different from those in the human body, and the prediction of drug properties was sometimes inadequate. The multi-well plate for 3D cell culture by HCS, with which JVCKENWOOD has concluded a marketing alliance, enables the cultivation of cells under conditions close to those of human organs using the company's proprietary BIOMIMESYS® technology. The use of 3D cultured cells for in-vitro studies is expected to contribute to the development of new drugs as it will allow for more accurate testing. The global market for 3D cell culture is expected to expand from approximately 150 billion yen in 2020 to approximately 400 billion yen in 2027, at an average annual growth rate of 15%, and there are high expectations for both the technology and the market.

JVCKENWOOD will begin developing sales of HCS products through collaboration with AS ONE Corporation, which has a diverse sales network in the research, industrial, and medical fields with advanced products, information, and logistics.

https://hcs-pharma.com/jvckenwood-corporation-and-hcs-pha...